The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone
- 19 June 2010
- journal article
- pharmacogenetics
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 66 (11) , 1109-1117
Abstract
Purpose To evaluate the role of cytochrome 450 2D6 (CYP2D6) and ABCB1 variants on plasma risperidone concentrations and treatment response in 83 drug-naive patients experiencing a first episode of psychosis. Methods All patients were treated with risperidone for 8 weeks. The CYP2D6 genotyping was performed by allele-specific PCR–restriction fragment length polymorphism analysis (for alleles *3,*4,*6) and long-distance PCR (for duplications and allele *5), while real-time PCR analysis was used for the ABCB1 G2677T/A and C3435T variants. Plasma concentrations of risperidone and 9-OH risperidone were measured by high-performance liquid chromatography. Results The number of patients with the CYP2D6 wild type (wt)/wt, wt/mutation (mut) and mut/mut genotype was 43, 32 and 8, respectively. The number of patients with the ABCB1 2677G/G, G/T and T/T variants was 29, 42 and 12, respectively; those with the 3435CC, C/T and T/T variants was 25, 37 and 21, respectively. The CYP2D6 genotype had a strong effect on the steady-state dose-corrected plasma levels (C/D) of risperidone, its 9-OH metabolite and the active moiety, while the ABCB1 2677 T/T and 3435 T/T genotypes has similarly strong effects on the active moiety C/D. The CYP2D6 poor metabolizers had a significantly higher risperidone C/D and active moiety C/D and lower 9-OH risperidone C/D. The ABCB1 3435 T allele and the ABCB1 2667 T-3435 T haplotype carriers were more frequent among subjects without extrapyramidal syndromes. Patients showed significant improvements in positive and general symptoms, but not in negative symptoms. These changes were not related to variations in genetic and drug concentration data. Conclusion Our findings suggest that CYP2D6 and ABCB1 G2677T and C3435T may be useful determinants of risperidone plasma concentrations, but the clinical implications of these associations in relation to treatment response and side-effects remain unclear.Keywords
This publication has 29 references indexed in Scilit:
- Polymorphism of Human Cytochrome P450 2D6 and Its Clinical SignificanceClinical Pharmacokinetics, 2009
- Clinical Significance of a CYP2D6 Poor Metabolizer -A Patient With Schizophrenia on Risperidone TreatmentTherapeutic Drug Monitoring, 2008
- ABCB1 Polymorphisms Influence Steady-State Plasma Levels of 9-Hydroxyrisperidone and Risperidone Active MoietyTherapeutic Drug Monitoring, 2008
- Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of researchMolecular Psychiatry, 2007
- A Study of Genetic (CYP2D6 and ABCB1) and Environmental (Drug Inhibitors and Inducers) Variables That May Influence Plasma Risperidone LevelsPharmacopsychiatry, 2007
- Effects of various factors on steady‐state plasma concentrations of risperidone and 9‐hydroxyrisperidone: lack of impact of MDR‐1 genotypesBritish Journal of Clinical Pharmacology, 2004
- Possible Relationship between Combined Plasma Concentrations of Risperidone plus 9-Hydroxyrisperidone and Extrapyramidal SymptomsNeuropsychobiology, 2001
- Plasma Concentrations of Risperidone and its 9-Hydroxy Metabolite and their Relationship to Dose in Schizophrenic Patients: Simultaneous Determination by a High Performance Liquid Chromatography with Electrochemical DetectionPharmacopsychiatry, 1998
- Rapid detection of CYP2D6 null alleles by long distance-and multiplex-polymerase chain reactionPharmacogenetics, 1996
- A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTSActa Psychiatrica Scandinavica, 1970